Brelovitug Shows Continued Improvement in Chronic Hepatitis D Beyond Week 24

This announcement highlights data from the AZURE-1 study indicating that brelovitug responses in patients with chronic hepatitis D continued to improve beyond the 24-week treatment mark. Douglas Dieterich, MD, provides insights into the sustained efficacy observed with this treatment.

Originally published by gnews